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Inflammatory proteases (mast cell tryptase and trypsins) cleave protease-activated receptor 2 (PAR2 ) on spinal afferent neurons and
cause persistent inflammation and hyperalgesia by unknown mechanisms. We determined whether transient receptor potential vanilloid
receptor 1 (TRPV1), a cation channel activated by capsaicin, protons, and noxious heat, mediates PAR2-induced hyperalgesia. PAR2 was
coexpressed with TRPV1 in small- to medium-diameter neurons of the dorsal root ganglia (DRG), as determined by immunofluores-
cence. PAR2 agonists increased intracellular [Ca
2] ([Ca 2]i ) in these neurons in culture, and PAR2-responsive neurons also responded
to the TRPV1 agonist capsaicin, confirming coexpression of PAR2 and TRPV1. PAR2 agonists potentiated capsaicin-induced increases in
[Ca 2]i in TRPV1-transfected human embryonic kidney (HEK) cells and DRG neurons and potentiated capsaicin-induced currents in
DRG neurons. Inhibitors of phospholipase C and protein kinase C (PKC) suppressed PAR2-induced sensitization of TRPV1-mediated
changes in [Ca 2]i and TRPV1 currents. Activation of PAR2 or PKC induced phosphorylation of TRPV1 in HEK cells, suggesting a direct
regulation of the channel. Intraplantar injection of a PAR2 agonist caused persistent thermal hyperalgesia that was prevented by antag-
onism or deletion of TRPV1. Coinjection of nonhyperalgesic doses of PAR2 agonist and capsaicin induced hyperalgesia that was inhibited
by deletion of TRPV1 or antagonism of PKC. PAR2 activation also potentiated capsaicin-induced release of substance P and calcitonin
gene-related peptide from superfused segments of the dorsal horn of the spinal cord, where they mediate hyperalgesia. We have identified
a novel mechanism by which proteases that activate PAR2 sensitize TRPV1 through PKC. Antagonism of PAR2 , TRPV1, or PKC may
abrogate protease-induced thermal hyperalgesia.
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Introduction
Proteases from the circulation, inflammatory cells, epithelial
cells, and neurons, which are generated during injury, cleave
protease-activated receptors (PARs) to regulate hemostasis, in-
flammation, pain, and healing (Ossovskaya and Bunnett, 2004).
Cleavage exposes tethered ligand domains that bind and activate
cleaved receptors. Thrombin activates PAR1, PAR3, and PAR4
(Vu et al., 1991; Ishihara et al., 1997; Kahn et al., 1998), and
factors VIIa and Xa activate PAR2 and PAR1 (Camerer et al.,
2000). Mast cell tryptase activates PAR2 (Corvera et al., 1997;
Molino et al., 1997), and neutrophil cathepsin G activates PAR4
(Sambrano et al., 2000). Pancreatic and extrapancreatic trypsins
activate PAR2 and PAR4 (Nystedt et al., 1994; Kahn et al., 1998;
Alm et al., 2000; Sawada et al., 2000; Cottrell et al., 2004).
Many of the effects of proteases that activate PAR2 are medi-
ated by receptors in the peripheral nervous system. PAR2 is ex-
pressed by dorsal root ganglia (DRG) neurons containing sub-
stance P (SP) and calcitonin gene-related peptide (CGRP)
(Steinhoff et al., 2000), which control inflammation and pain.
PAR2 agonists stimulate SP and CGRP release from the periph-
eral projections of DRG neurons in the skin and intestine, causing
edema and hyperemia (“neurogenic inflammation”; Steinhoff et
al., 2000; Cenac et al., 2002, 2003). They also stimulate airway
constriction (Ricciardolo et al., 2000) and gastric mucus secre-
tion (Kawabata et al., 2001b) by neurogenic mechanisms. In-
traplantar injection of PAR2 agonists induces neuropeptide re-
lease from the central projections of DRG neurons in the spinal
cord to activate nociceptive neurons and cause hyperalgesia
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(Kawabata et al., 2001a; Vergnolle et al., 2001). Activation of
PAR2 in the pancreas and intestine also excites nociceptive neu-
rons and induces visceral hyperalgesia (Hoogerwerf et al., 2001;
Coelho et al., 2002; Kirkup et al., 2003). However, the mecha-
nisms by which PAR2 regulates neuronal function to cause in-
flammation and hyperalgesia are unknown.
We investigated the contribution of transient receptor poten-
tial vanilloid receptor 1 (TRPV1) to PAR2-mediated hyperalge-
sia. TRPV1 is a nonselective cation channel expressed by nocicep-
tive neurons that makes a major contribution to inflammatory
and thermal hyperalgesia (Caterina et al., 1997; Caterina et al.,
2000; Davis et al., 2000). Exogenous (capsaicin and ethanol) and
endogenous (protons of pH 6.0, noxious heat of 43°C, and
anandamide) factors directly activate TRPV1 (Caterina et al.,
1997; Zygmunt et al., 1999; Trevisani et al., 2002). Inflammatory
agents that activate G-protein-coupled receptors [e.g., bradyki-
nin, ATP, and prostaglandin E2 (PGE2) (Tominaga et al., 2001;
Vellani et al., 2001; Hu et al., 2002; Rathee et al., 2002; Mohapatra
and Nau, 2003)] and receptor-tyrosine kinases (e.g., NGF; Shu
and Mendell, 1999; Chuang et al., 2001) can indirectly sensitize
TRPV1 to cause hyperalgesia.
We hypothesized that PAR2 sensitizes TRPV1 to induce hy-
peralgesia. Sensitization is suggested by the observations that
PAR2 agonists enhance capsaicin-evoked CGRP release from
DRG and fos expression in spinal neurons (Hoogerwerf et al.,
2001). The TRPV1 antagonist capsazepine attenuates PAR2-
stimulated thermal hyperalgesia (Kawao et al., 2002) and gastric
mucus secretion (Kawabata et al., 2002). However, direct evi-
dence of PAR2-induced sensitization of TRPV1 is lacking and the
molecular mechanisms are unknown. Our aims were (1) to de-
termine whether PAR2 activation sensitizes TRPV1 Ca
2 signal-
ing and TRPV1 currents to induce thermal hyperalgesia; (2) to
elucidate the mechanism of sensitization; (3) to determine
whether PAR2 activation phosphorylates TRPV1; and (4) to in-
vestigate whether PAR2 activation potentiates TRPV1-induced
release of neuropeptides from the central projections of nocicep-
tive DRG neurons.
Materials and Methods
Animals. Sprague Dawley rats (male, 200 –250 gm) and C57BL/6 mice
(6 – 8 weeks) were from Charles River Laboratories. TRPV1/ and
TRPV1/ (C57BL/6J) mice were from The Jackson Laboratory (Bar
Harbor, ME). Littermates were used in control experiments. Procedures
were approved by Institutional Animal Care and Use Committees.
PAR activators and inhibitors. Synthetic peptides corresponding to
the tethered ligands [activating peptides (APs)] can directly activate
PAR1, PAR2, and PAR4 and are useful tools for investigating receptor
functions. PAR2-AP (SLIGRL-NH2), corresponding to the tethered
ligand of the rat receptor, and an analog of PAR1-AP (TFLLR-NH2),
which specifically activates PAR1, were synthesized and purified as
described (Steinhoff et al., 2000). The reverse peptide sequences
(PAR-RP), which do not activate PARs, were used for controls.
Tryptase was purified from human lung (Steinhoff et al., 2000). Bo-
vine pancreatic trypsin was from Worthington (Lakewood, NJ).
Thrombin, U73122 [1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-
yl)amino)hexyl]-1H-pyrrole-2,5-dione], GFX [(2-[1-(3-dimethyl-
aminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide],
Go¨6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-
5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole, and phorbol-12-myris-
tate 13-acetate (PMA) were from Calbiochem (La Jolla, CA). We used
concentrations of agonists and antagonists that we have previously
shown to selectively activate PAR1 and PAR2 in neurons (Steinhoff et
al., 2000; de Garavilla et al., 2001) and that effectively and selectively
inhibit the targeted enzymes (Bohm et al., 1996).
Cell and neuronal culture. Human embryonic kidney 293 (HEK293)
cells stably expressing human TRPV1 were generated and maintained in
Eagle’s MEM with Earle’s BSS medium (MEM), 10% fetal bovine serum,
and geniticin (400 mg/l) (Hayes et al., 2000). DRG from thoracic and
lumbar spinal cord of rats were minced in cold HBSS and incubated for
60 –90 min at 37°C in DMEM containing (in mg/ml): 0.5 trypsin, 1
collagenase type IA, and 0.1 DNase type IV (Sigma, St. Louis, MO) (Stein-
hoff et al., 2000). Soybean trypsin inhibitor (Sigma) was added to neutralize
trypsin. Neurons were pelleted, suspended in DMEM containing 10% fetal
bovine serum, 10% horse serum, 100 U/ml penicillin, 0.1 mg/ml streptomy-
cin, 2 mM glutamine, and 2.5g/ml DNase type IV, plated on glass coverslips
coated with Matrigel (BD Biosciences, Bedford, MA), and cultured for 2–3 d.
Reverse transcription-PCR. Total RNA from HEK293-TRPV1 (1 g)
was reverse-transcribed with oligo(dT)15 and avian myeloblastosis virus
reverse transcriptase (Promega, Madison, WI). PCR reactions used
primers specific to the C terminus of human PAR2 (forward, 5-ccctttg-
tatgtcgtgaagcagac-3; reverse, 5-ttcctggagtgtttctttgaggtg-3) and human
PAR1 (forward, 5-agcaaaccatccaggtgc-3; reverse, 5-tgttataactgctgggatcg-
3). Control reactions omitted reverse transcriptase. Products were separated
by electrophoresis (2% agarose gel), detected using ethidium bromide, and
sequenced.
Immunofluorescence. Rats were transcardially perfused with 4% para-
formaldehyde in 100 mM PBS, pH 7.4. DRG were fixed overnight and
embedded on optimal cutting temperature compound, and 14 m sec-
tions were prepared (Steinhoff et al., 2000). Cultured DRG were fixed
with 4% paraformaldehyde for 20 min at 4°C. Sections and cultures were
incubated with the primary antibodies for 16 hr at 4°C: PAR2, rabbit
antibody (Ab) B5 to the N terminus of rat PAR2 (Dr. M. Hollenberg,
University of Calgary; Kong et al., 1997), 1:250 –1:500; and TRPV1,
guinea pig Ab to the C terminus of rat TRPV1 (Chemicon, Temecula,
CA), 1:1000 –1:20,000. Sections and cultures were incubated with anti-
rabbit or anti-guinea pig IgG conjugated to Texas Red or FITC (Jackson
ImmunoResearch, West Grove, PA). In the case of the sections, the
TRPV1 signal was amplified using a tyramide signal amplification system
(PerkinElmer Life Sciences, Boston, MA). Specimens were observed us-
ing a Zeiss (Thornwood, NY) Axiovert and an MRC 1000 laser scanning
confocal microscope (Bio-Rad, Hercules, CA). In controls, primary antibod-
ies were preincubated with 10M peptides used for immunization for 48 hr
at 4°C, which abolished staining.
Immunoprecipitation and Western blotting. HEK-TRPV1 cells were
maintained overnight in MEM and 0.1% BSA, incubated with agonists
for 10 min at 37°C, and lysed with radioimmunoprecipitation assay
buffer. Samples (500l) were incubated with rabbit anti-human TRPV1
(1 g/ml, overnight, 4°C; Chan et al., 2003). Protein A/G Plus (Santa
Cruz Biotechnology, Santa Cruz, CA; 30 l) was added and mixed for 2
hr at 4°C. Beads were pelleted, suspended in 2 SDS loading buffer, and
boiled for 5 min, and the supernatant was fractionated by SDS-PAGE
(8% gel). Proteins were transferred to polyvinylidene difluoride mem-
branes (Millipore, Billerica, MA). Membranes were incubated with Ab to
phosphoserine (Zymed, South San Francisco, CA; 1:1000 in PBS, 2%
BSA, and 0.1% Tween 20, overnight, 4°C) and then with goat anti-rabbit
horseradish peroxidase (Jackson ImmunoResearch; 1:10,000, 1 hr, room
temperature). Immunoreactive proteins were detected by enhanced
chemiluminescence (Amersham Biosciences, Piscataway, NJ). To ensure
equal loading, membranes were stripped in 62.5 nM Tris-HCl, pH 6.8, 2%
SDS, and 100 mM 2-mercaptoethanol and re-probed with anti-TRPV1
(0.2 g/ml, overnight, 4°C).
Measurement of intracellular [Ca2]. HEK293-TRPV1 cells and DRG
neurons were incubated in HBSS, 0.1% BSA, and 20 mM HEPES, pH 7.4,
containing 2.5–5 M fura-2 AM (Molecular Probes, Eugene, OR) for
30 – 45 min at 37°C (Steinhoff et al., 2000). Coverslips were mounted in
an open chamber at 37°C. Fluorescence of individual cells was measured
at 340 and 380 nm excitation and 510 nm emission using a Zeiss Axiovert
microscope, an intensified CCD video camera (Stanford Photonics,
Stanford, CA), and a video microscopy acquisition program (Axon In-
struments, Union City, CA). Test substances were directly added to the
chamber (50 l injection). Each coverslip received only one treatment
with PAR2-AP or -RP followed by capsaicin. DRG preparations were
challenged with KCl (50 mM) at the end of each experiment. In some
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experiments, cells were pretreated with inhibitors for 30 min at 37°C
before the challenge with test compounds. The magnitude of responses
to test agents was calculated as the increase above baseline. Results are
expressed as the 340:380 nm emission ratio, which is proportional to the
intracellular [Ca 2] ([Ca 2]i). The effects of the inhibitors on sensitiza-
tion of TRPV1 were calculated as a ratio and are expressed as a percentage
of the potentiation observed in positive controls (100%) pretreated with
PAR2 agonists or PMA. To determine the source of PAR-induced in-
creases in [Ca 2]i, some experiments were completed in Ca
2-free
buffer.
Electrophysiology. DRG neurons were placed in an open recording
chamber and perfused with Ringer’s solution
(in mM: 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10
HEPES, and 10 glucose, pH 7.4 at 21°C). Mem-
brane currents and voltages were recorded
from small- and medium-diameter neurons
under the whole-cell configuration with an
Axon Instruments 1D patch-clamp amplifier.
Recording pipettes (outer diameter, 1.65 
0.05 m) had resistances of 2– 4 M when
filled with buffer (in mM: 140 KCl, 5 MgCl2, 4
Na2ATP, 0.3 Na3GTP, 2.5 CaCl2, 5 EGTA, and
10 HEPES, pH 7.2). After establishing the
whole-cell configuration, neurons were re-
quired to maintain a zero-current potential of
less than 45 mV for 5 min. Voltage changes
evoked by the injection of current or applica-
tion of PAR2 agonists (applied by fast perfusion
for 3 min) were filtered at 2 kHz and sampled at
20 kHz using pClamp 8 software (Axon Instru-
ments). To assess excitability, the rheobase was
measured by step increases of the amount of
injected current (40 pA for 200 msec every 30
sec) under the current-clamp mode (Abdulla
and Smith, 1997). Capsaicin-induced currents
were recorded under the voltage-clamp mode
when membrane potential was held at60 mV
(Nicol and Cui, 1994). Whole-cell currents
evoked by capsaicin were filtered at 1 kHz and
sampled at 1 KHz. Capsaicin was administered
by fast perfusion for 150 msec to 1 sec, adjusted
according to the amplitude of the current.
PAR2-AP, trypsin, PAR2-RP, and inactivated
trypsin were also applied by fast perfusion for 3
min. Because of limited quantities, tryptase
was “puffed” into the neurons (Picospritzer
II; General Valve, Fairfield, NJ). In some ex-
periments, neurons were pretreated with in-
hibitors for 5 min. Rheobase is expressed as a
change from basal (normalized to a basal
value of 1) and as a percent change from basal
rheobase. Membrane potential is expressed
as absolute values (millivolts). TRPV1 cur-
rents are expressed as absolute values (nano-
amperes) or as fold change from basal.
Paw withdrawal latency. PAR2-AP, PAR2-RP
(in sterile 0.9% saline), and capsaicin (in 80%
sterile saline, 10% ethanol, and 10% Tween 80)
were administered by intraplantar injection in
mice (final, 10 l/paw) under light halothane
(5%) anesthesia (Vergnolle et al., 2001). Cap-
sazepine (35 mg/kg, s.c.) was administered 30
min before the intraplantar injections. The
protein kinase C (PKC) inhibitor GFX (1 g in
5 l) or vehicle (saline) was administered by
intraplantar injection immediately after the in-
traplantar injection of distilled water (2 l) to
osmotically shock cells. These animals received
PAR2-AP (1 ng) and capsaicin (1 g) 15 min later (final, 5 l). The
latency of paw withdrawal to a radiant heat stimulus was measured be-
fore and after the intraplantar injections of test substances using a plantar
test apparatus (Ugo Basile, Milan, Italy). Thermal hyperalgesia was de-
fined as a decrease in the withdrawal latency compared with the basal
measurement. The investigator was unaware of the genotype of the
TRPV1/ and TRPV1/ mice before the experiments.
Neuropeptide release from the dorsal horn of the spinal cord. Slices (0.4
mm) of the dorsal spinal cord of rats were superfused at 0.4 ml/min with
Krebs’ solution (in mM: 119 NaCl, 25 NaHCO3, 1.2 KH2PO4, 1.5 MgSO4,
Figure 1. PAR2 activation sensitizes TRPV1 in transfected cells. a, HEK-TRPV1 cells express PAR1 and PAR2. mRNA for PAR1 (lane
2) and PAR2 (lane 4) was detected in HEK-TRPV1 cells by RT-PCR. Lanes 1 and 3 are controls (no RT). Results are representative of
three experiments. b– g, Cells were exposed to PAR2-AP or -RP (100M), trypsin (10 nM), PMA (5M), or vehicle for 5 min and
were then challenged with capsaicin. PAR2 agonists (c, e– g) and PMA ( g) potentiated responses to capsaicin. Inhibition of PLC
(U73122, 5M) and PKC (GFX and Go¨6976, 1 and 0.1M, respectively) suppressed the potentiation ( g). Results in g are expressed
as a percentage of the positive control (cells treated with PAR2 agonists or PMA). *p 0.05 compared with PAR2-RP or saline ( f),
PMA, PAR2-AP, or trypsin ( g). Try, Trypsin; AP, PAR2-AP; n	 120 –1040 cells.
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2.5 CaCl2, 4.7 KCl, and 11 D-glucose containing 0.1% BSA, 1 M phos-
phoramidon, and 1 M captopril; 37°C, 95% O2 and 5% CO2). Slices
were pretreated with PAR2-AP, PAR2-RP, or vehicle for 20 min. The
superfusate was then collected at 10 min intervals. After two basal collec-
tions, slices were perfused with capsaicin for 10 min. Superfusate was
analyzed for SP-like immunoreactivity (LI) and CGRP-LI by ELISA
(Steinhoff et al., 2000). Peptide release was determined by subtracting
basal levels from concentrations measured during and immediately after
exposure to capsaicin. Results are expressed as femtomoles of peptide per
gram of weighed tissue per 20 min period. The highest concentration of
capsaicin, PAR2-AP, and PAR2-RP did not interfere with the assays.
Statistical analysis. Results are expressed as mean  SEM and were
compared by ANOVA and Student’s t test with Bonferroni correction or
by Dunnett’s test. Differences were considered significant at p 0.05.
Results
PAR2 agonists sensitized TRPV1 Ca
2 responses in HEK-
TRPV1 cells by activation of phospholipase C and PKC
We determined whether PAR2 activation sensitizes TRPV1 ex-
pressed in HEK293 cells. By using reverse transcription (RT)-
PCR, we found that these cells endogenously expressed PAR2
mRNA (Fig. 1a). We measured [Ca 2]i to assess activation of
PAR2, which couples to mobilization of Ca
2, and TRPV1, a
nonselective cation channel with preference for Ca 2 ions.
PAR2-AP (100 M) and trypsin (10 nM) rapidly increased
[Ca 2]i, confirming expression of functional PAR2 (Fig. 1c,e).
This rapid increase in [Ca 2]i was fully maintained in Ca
2-free
medium and is thus attributable to mobilization of intracellular
Ca 2 (data not shown). PAR2-RP, which does not activate PAR2,
had no effect on [Ca 2]i (Fig. 1b). Exposure to PAR2-AP or tryp-
sin potentiated Ca 2 responses to the selective TRPV1 agonist
capsaicin applied 5 min later (1–100 nM; Fig. 1b–f). The response
to 10 nM capsaicin was increased 127  12% by PAR2-AP (100
M) and 79  10% by trypsin (10 nM), compared with cells
treated with PAR2-RP or vehicle. PAR2-AP increased both the
potency and the efficacy of the response to capsaicin (Fig. 1f).
Thus, PAR2 activation sensitizes TRPV1. Conversely, pretreat-
ment with capsaicin (10 nM) did not affect the increase in [Ca 2]i
to PAR2-AP applied 5 min later (10 –100 M; data not shown),
indicating that TRPV1 activation does not sensitize PAR2.
The membrane phospholipid phosphatidylinositol-4,5-
bisphosphate (PIP2) and phospholipase C (PLC), which cata-
lyzes the hydrolysis of PIP2 to 1,4,5-inositol trisphosphate (InsP3)
and diacylglycerol (DAG), regulate TRPV1 (Chuang et al., 2001;
Prescott and Julius, 2003). We investigated whether PAR2-
induced potentiation of TRPV1 was mediated by PLC. Pretreat-
ment with the PLC inhibitor U73122 (5 M, 30 min) attenuated
the magnitude of the response to capsaicin (10 nM) by 31 4%
when compared with cells treated with vehicle (data not shown).
These results are consistent with the observation that the inhibi-
tory action of PIP2 on TRPV1 is enhanced by suppression of tonic
PLC activity (Chuang et al., 2001; Hu et al., 2002; Prescott and
Julius, 2003). Nonetheless, inhibition of PLC suppressed the po-
tentiation of capsaicin responses induced by PAR2-AP by80%
and eliminated potentiation by trypsin, reducing the response
below levels in vehicle-treated cells. Thus, when compared with
the positive control (capsaicin response in cells treated with
PAR2-AP or trypsin, 100%), the response to capsaicin was 61
13% after U73122 and PAR2-AP and 38 9% after U73122 and
trypsin (Fig. 1g).
DAG generated by PLC from membrane phospholipids ac-
tivates PKC. Because PKC can directly phosphorylate TRPV1 and
thereby sensitize responses to TRPV1 agonists (Premkumar and
Ahern, 2000; Vellani et al., 2001; Crandall et al., 2002; Numazaki
et al., 2002), we hypothesized that PKC mediates PAR2-induced
sensitization of TRPV1. The PKC activator PMA (5 M, 5 min)
enhanced the response to 10 nM capsaicin (Fig. 1g). This effect
was reduced by
50% by the general PKC inhibitor GFX (1 M,
30 min). Similarly, GFX inhibited PAR2-induced potentiation of
responses to capsaicin60%. The effects of capsaicin after GFX
and PAR2-AP and GFX and trypsin were 71 5% and 73 6%,
respectively, when compared with the positive control (Fig. 1g).
To characterize the isozymes of PKC that mediate PAR2-induced
sensitization of TRPV1, we used Go¨6976, an inhibitor of conven-
tional PKC isoforms (,1,2, and ) but not the PKC isoform.
Pretreatment with Go¨6976 (0.1 M, 30 min) inhibited PAR2-
induced sensitization of responses to 10 nM capsaicin by
50%.
The effect of capsaicin after Go¨6976 and PAR2-AP was 77 7%
of the positive control (Fig. 1g). Pretreatment with GFX or
Go¨6976 did not affect the responses of capsaicin in cells treated
with vehicle and PAR2-RP (data not shown).
PAR2 agonists sensitized TRPV1 Ca
2 responses in DRG
neurons by activation of PLC and PKC
To determine whether PAR2 and TRPV1 are coexpressed in DRG
neurons, we localized the proteins by immunofluorescence in
tissue sections and cultures and measured [Ca 2]i in DRG cul-
tures to selective agonists. Immunoreactive PAR2 and TRPV1
were colocalized in small- and medium-diameter (30m) neu-
rons in sections of DRG from adult rat (Fig. 2a, top panels), and
expression was retained in culture (Fig. 2a, bottom panels). Cap-
saicin (100 nM) increased [Ca 2]i in 52  5% of neurons re-
sponding to KCl (50 mM; n	 103 total neurons). PAR2-AP (100
M) increased [Ca 2]i in 32  2% (n 	 439) of neurons, and
trypsin (10 nM) increased it in 44  9% (n 	 34) of neurons,
whereas PAR2-RP was ineffective (Fig. 2b– e). We have previously
shown that tryptase mobilizes Ca 2 in a similar proportion of
neurons by activating PAR2 (Steinhoff et al., 2000). The rapid
increase in [Ca 2]i was fully maintained in Ca
2-free medium
and is thus attributable to mobilization of intracellular Ca 2
(data not shown). Most of the neurons responding to PAR2-AP
(79  3%) and all of the neurons responding to trypsin were
capsaicin-sensitive (Fig. 2d,e). Thus, PAR2 and TRPV1 are mostly
coexpressed in DRG neurons.
We examined whether PAR2 activation sensitizes TRPV1-
mediated increases in [Ca 2]i in neurons. Exposure to PAR2-AP
(100 M) and trypsin (10 nM) potentiated the response to capsa-
icin (100 nM) applied 5 min later by 53 7% (n	 231 capsaicin-
responsive neurons) and 88 24% (n	 21), respectively, com-
pared with control cells pretreated with PAR2-RP (100 M; n 	
140) or vehicle (PBS, 1:100; n	 17; Fig. 2b– g). PAR2 activation
also increased the proportion of neurons responding to capsaicin
(Fig. 2h). After pretreatment with PAR2-RP and vehicle, 46 3%
(n 	 304 total neurons) and 53  9% (n 	 32), respectively, of
neurons were capsaicin-sensitive. However, after pretreatment
with PAR2-AP and trypsin, 65 3% (n	 357) and 62 8% (n	
34), respectively, of neurons responded to capsaicin. Pretreat-
ment with capsaicin (10 nM) did not affect the response to
PAR2-AP applied 5 min later (10 –100 M; data not shown).
Thus, PAR2 activation potentiates the magnitude of responses to
capsaicin and increases the proportion of capsaicin-responsive
neurons, indicating sensitization of TRPV1.
Inhibition of PLC with U73122 (5 M, 30 min) had no effect
on the magnitude of the Ca 2 response to capsaicin (100 nM) but
inhibited the PAR2-AP-induced potentiation of the response to
capsaicin by 90%; the effect of capsaicin after U73122 and
PAR2-AP was 65  6% compared with the positive control of
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vehicle and PAR2-AP (100%; n	 72 total
neurons; Fig. 2g). Activation of PKC with
PMA (5 M) potentiated the increase in
[Ca 2]i to capsaicin (n 	 45) compared
with cells pretreated with the vehicle (n	
35). This effect was abolished by GFX (1
M, 30 min; n 	 22; Fig. 2g). GFX also
inhibited PAR2-AP-induced potentiation
of the response to capsaicin by80%; the
effect of capsaicin after GFX and PAR2-AP
was 73  7% compared with the positive
control (n 	 60; Fig. 2g). Pretreatment
with Go¨6976 (0.1 M, 30 min) inhibited
PAR2-induced sensitization of the re-
sponse to capsaicin by80%; the effect of
capsaicin after Go¨6976 and PAR2-AP was
73  16% compared with the positive
control (n	 37; Fig. 2g).
Thus, observations in both HEK-
TRPV1 cells and DRG neurons indicate
that PAR2 agonists sensitize TRPV1 by a
mechanism that is dependent on PLC and
the conventional isoforms of PKC.
PAR1 agonists did not sensitize TRPV1
Ca 2 responses in HEK-TRPV1 or DRG
neurons
To evaluate the specificity of PAR2-
mediated sensitization of TRPV1, we
investigated whether agonists of PAR1
sensitize this channel. PAR1 was endog-
enously expressed in HEK-TRPV1 cells
(Fig. 1a) and is also present in small-
diameter DRG neurons (de Garavilla et al.,
2001). PAR1-AP (100M) rapidly increased
[Ca2]i in HEK-TRPV1 cells (Fig. 3b) and
DRG neurons (Fig. 3d), whereas PAR1-RP
was ineffective. PAR1-AP increased [Ca
2]i
in 56 5% of DRG neurons (n	 117 total
neurons), 54 6% of which also responded
to capsaicin. The rapid increase in [Ca2]i in
HEK-TRPV1 cells and DRG neurons was
still observed in Ca2-free medium and is
thus attributable to mobilization of intracel-
lular Ca2 (data not shown). PAR1-AP did
not affect the magnitude of the Ca2
response to 3 or 10 nM capsaicin in HEK-
TRPV1 cells (Fig. 3e) or to 100 nM capsaicin
in DRG neurons (n 	 53 capsaicin-
responsive neurons; Fig. 3f). PAR1-AP also
did not influence the number of capsaicin-
responsive neurons (Fig, 3g). Thus, activa-
tion of PAR2 selectively sensitizes TRPV1.
PAR2 agonists increased excitability of
DRG neurons
Activation of PAR2 on enteric neurons re-
sults in depolarization and sustained hy-
perexcitability (Linden et al., 2001; Gao et
al., 2002; Reed et al., 2003). We therefore determined whether
PAR2 activation depolarized small- and medium-diameter DRG
neurons in culture and lowered their firing threshold, thereby
increasing their excitability to other stimuli, by measuring the
rheobase (minimum current to evoke one action potential in the
current-clamp mode). The average initial rheobase was 0.83 
0.11 nA and was not statistically different between any of the
experimental groups of neurons. Trypsin (10 nM, 3 min) and
Figure 2. PAR2 activation sensitizes TRPV1 in DRG neurons. a, Colocalization (arrows) of immunoreactive PAR2 and TRPV1 in
tissue sections of DRG neurons (top panels) and in cultured DRG neurons (bottom panels). Scale bars: top panels, 50m; bottom
panels, 25m. b– h, Neurons were exposed to PAR2-AP or -RP (100M), trypsin (10 nM), PMA (5M) or vehicle for 5 min, and
were then challenged with capsaicin (100 nM). PAR2 agonists (c, e– h) and PMA ( g ) potentiated responses to capsaicin. Inhibition
of PLC (U73122, 5M) and PKC (GFX and Go¨6976, 1 and 0.1M, respectively) suppressed the potentiation ( g ). PAR2 activation
also increased the proportion of neurons that gave detectable responses to capsaicin (h). Results in g are expressed as a percentage
of the positive control (magnitude of capsaicin response in cells after PAR2 activation). *p0.05 compared with PAR2-RP or saline
( f, h) and PMA or PAR2-AP ( g ). AP, PAR2-AP; n	 17–231 neurons.
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tryptase (3.8 M pipette concentration, puffed onto cells) in-
duced a sustained decrease in the rheobase that was detected at 10
min and maintained for at least 50 min (50 min: trypsin, 59.6
9.6% decrease; n 	 7 total neurons; tryptase, 50.4  3.5% de-
crease; n 	 5; Fig. 4a,b). Inactivated trypsin [10 nM, 3 min, pre-
treated with soybean trypsin inhibitor (SBTI), 10 mg/ml, 30 min,
37°C] had no effect on the rheobase (Fig. 4b). Surprisingly,
PAR2-AP (50 M, 3 min) increased rheobase at 10 min by 31%
(Fig. 4a). However, PAR2-RP (50 M, 3 min) also increased the
rheobase at this time to a similar extent (44%), suggesting that the
increase in rheobase to PAR2-AP is nonspecific. At later time
points, PAR2-AP caused a sustained decrease in rheobase (50
min: 40.2 5.9%; n	 7), whereas PAR2-RP had no effect (Fig.
4a,b). The resting potential of neurons was 57.2 1.6 mV. Tryp-
sin, tryptase, and PAR2-AP depolarized neurons after 10 min
(trypsin, 11.0  2.1 mV; n 	 7; tryptase,
13.2 2.5 mV; n	 5; PAR2-AP, 4.9 2.3
mV; n	 7), but within 20 min, the mem-
brane potential had repolarized (Fig.
4c,d). Inactivated trypsin and PAR2-RP
had no effect on membrane potential (Fig.
4d). Thus, brief activation of PAR2 in-
duces a sustained hyperexcitability of
DRG neurons.
PAR2 agonists sensitized TRPV1
currents in DRG neurons by
activating PKC
To study the effect of activation of PAR2
on the activity of TRPV1, we measured
whole-cell currents induced by capsaicin
before and after PAR2 activation in DRG
neurons. Approximately 50% of small and
medium DRG neurons responded to brief
(150 msec–1 sec) application of capsaicin
(500 nM). Stable inward currents to re-
peated application (3 min interstimulus
interval) of capsaicin were recorded in
40 –50% of responsive neurons, whereas
capsaicin currents desensitized in other
neurons. Only neurons that did not ex-
hibit desensitization to two consecutive
capsaicin applications were selected for
further study. PAR2-AP (50 M, 3 min)
and trypsin (10 nM, 3 min) increased the
inward current induced by capsaicin (500
nM; Fig. 5a– c). This potentiation was ob-
served within 10 min of PAR2 activation
and was sustained for at least 60 min. For
example, at 30 min after application of
PAR2-AP or trypsin, the capsaicin-
induced TRPV1 current was significantly
increased by a 3.1- 0.6-fold change over
basal (n	 6 neurons) and 2.0- 0.1-fold
(n 	 10), respectively, compared with
controls treated with PAR2-RP (50 M, 3
min) or vehicle (Fig. 5a– c). The PKC in-
hibitor GFX (1 M, 5 min) abolished the
potentiation of the TRPV1 current in-
duced by PAR2-AP (1.1-  0.2-fold after
GFX and PAR2-AP; n	 4; compared with
4.5- 1.2-fold after vehicle and PAR2-AP;
Fig. 6a,b). However, GFX had minimal af-
fect on the basal TRPV1 current (Fig. 6c,d). Thus, transient acti-
vation of PAR2 causes sustained sensitization of TRPV1 by a
PKC-dependent process. In contrast, PAR1-AP (50 M, 3 min)
did not sensitize the capsaicin current (data not shown).
PAR2 agonists induced phosphorylation of TRPV1 in
HEK-TRPV1 cells
PKC can directly phosphorylate TRPV1 and thereby sensitize
responses to TRPV1 agonists (Numazaki et al., 2002). Because
PAR2-induced sensitization of TRPV1 requires PKC activation,
we hypothesized that PAR2 activation can modify phosphoryla-
tion of TRPV1. To assess phosphorylation of TRPV1, we immu-
noprecipitated the channel and probed Western blots for phos-
phoserine. PAR2-AP (100 M, 10 min; Fig. 7) or trypsin (10 nM,
10 min; data not shown) induced phosphorylation of TRPV1 in
Figure 3. PAR1 activation does not sensitize TRPV1 in transfected cells (a, b, e) or DRG neurons (c, d, f, g). HEK-TRPV1 cells (a, b,
e) or DRG neurons (c, d, f, g) were exposed to PAR1-AP or -RP (100 M) for 5 min and were then challenged with capsaicin. In
HEK-TRPV1 cells, PAR1-AP failed to potentiate the response to 3 or 10 nM capsaicin (b, e). In DRG, PAR1-AP failed to potentiate the
magnitude of the response to 100 nM capsaicin (d, f ) or affect the proportion of neurons that gave a detectable response to
capsaicin ( g ); n	 160 –320 cells, 28 –53 neurons.
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Figure 4. PAR2 activation excites DRG neurons in culture. Neurons were superfused for 3 min
with PAR2-AP or -RP (50M) or trypsin or SBTI-treated trypsin (10 nM) or puffed with tryptase
(3.8M). The rheobase (a, b) and membrane potential (c, d) were measured at the indicated
times. Trypsin and tryptase caused a sustained decrease in rheobase that was maintained for at
least 50 min. PAR2-AP caused a transient increase in rheobase at 10 min followed by a sustained
decrease ( a). This effect was nonspecific because PAR2-RP produced an identical transient
increase (data not shown) without a sustained effect on rheobase ( b) or a transient decrease in
membrane potential ( d). PAR2 agonists caused a transient decrease in membrane potential (c,
d). *p 0.01 compared with basal (a, b) or PAR2-RP and trypsin (Try) SBTI (c, d). Numbers in
parentheses are numbers of neurons.
Figure 5. PAR2 activation sensitizes TRPV1 currents. Neurons were superfused for 3 min with
PAR2-AP or -RP (50M), trypsin (10 nM), or vehicle. They were challenged at the indicated times
with capsaicin (500 nM), and currents were measured. a, Representative currents under basal
conditions and at 30 min after activation of PAR2. PAR2 activation caused a marked and sus-
tained increase in the capsaicin-induced current (a, b), and the increase observed 30 min after
activation is shown in c. *p  0.01 compared with basal ( b) or vehicle and PAR2-RP ( c).
Numbers in parentheses are numbers of neurons.
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HEK-TRPV1 cells, whereas PAR2-RP (100M) or vehicle had no
effect. PMA (10 M, 10 min) also increased the phosphorylation
of TRPV1, whereas vehicle (DMSO, 1:250) had no effect (Fig. 7).
Thus, stimulation of PAR2 directly phosphorylates TRPV1.
PAR2 agonists induced thermal hyperalgesia by a mechanism
that was mediated by TRPV1 and protein kinase C
The intraplantar injection of trypsin, tryptase, and PAR2-AP, at
doses that do not cause detectable inflammation of the paw, in-
duces sustained thermal and mechanical hyperalgesia (Vergnolle
et al., 2001). Because TRPV1 is an important mediator of thermal
hyperalgesia and inflammatory pain (Caterina et al., 1997; Tomi-
naga et al., 1998; Zygmunt et al., 1999; Caterina et al., 2000; Davis
et al., 2000), we evaluated the role of TRPV1 in PAR2-induced
thermal hyperalgesia using pharmacological and genetic ap-
proaches. Intraplantar injection of a subinflammatory dose of
PAR2-AP in C57BL/6 mice (1 g/paw; Vergnolle et al., 2001),
decreased the latency of paw withdrawal from a thermal stimulus
for 30 min to at least 4 hr, indicative of sustained thermal hyper-
algesia (Fig. 8a). Intraplantar PAR2-RP (1g/paw) did not affect
withdrawal latency. Pretreatment with the TRPV1 antagonist
capsazepine (35 mg/kg, s.c.) markedly inhibited PAR2-induced
hyperalgesia compared with animals treated with vehicle (Fig.
8a). In TRPV1/ mice, intraplantar injection PAR2-AP but not
PAR2-RP (1 g/paw) also caused a sustained decrease in latency
of paw withdrawal (Fig. 8b). In contrast, PAR2-AP did not affect
the latency of withdrawal in TRPV1/ mice. Thus, TRPV1 is
required for PAR2-induced thermal hyperalgesia.
To examine the capacity of PAR2-AP to sensitize TRPV1, we
Figure 6. PAR2 activation sensitizes TRPV1 currents by a PKC-dependent mechanism. Neu-
rons were superfused for 3 min with PAR2-AP or -RP (50M) and then challenged with capsaicin
(500 nM). PAR2 activation caused a marked increase in the capsaicin current, and the increase
was abolished by GFX (1M). GFX had no effect in neurons treated with PAR2-RP. Representa-
tive traces are shown in a and c, and pooled data are shown in b and d. *p0.01 compared with
vehicle and PAR2-AP. Numbers in parentheses are numbers of neurons.
Figure 7. Agonist of PAR2 induced phosphorylation of TRPV1. HEK-TRPV1 cells were exposed
to PAR2-AP or -RP (100M), PMA (10M), or DMSO (1:250) for 10 min. TRPV1 was immuno-
precipitated (IP), and Western blots (WB) were probed for phosphoserine ( a). Blots were then
stripped and reprobed to TRPV1 to ensure equal loading ( b). Activation of PAR2 and PKC induced
serine phosphorylation of TRPV1. Representative blots are shown.
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simultaneously administered doses of
PAR2-AP and capsaicin that alone did not
cause hyperalgesia. By administration of
graded doses of PAR2-AP (1–500 ng/paw)
to C57BL/6 mice, we determined that 1 ng
PAR2-AP had no effect on thermal hyper-
algesia (Fig. 8c). Capsaicin (1g/paw) also
did not cause thermal hyperalgesia (Fig.
8d). However, coinjection of PAR2-AP (1
ng/paw) and capsaicin (1 g/paw) de-
creased the latency of paw withdrawal,
suggesting that PAR2 sensitizes TRPV1
to capsaicin (Fig. 8d). Similarly, in
TRPV1/ mice, coinjection of PAR2-AP
(1 ng/paw) and capsaicin (1 g/paw) de-
creased the latency of paw withdrawal for
30 min to 2 hr (Fig. 8e). In TRPV1/
mice, coinjection of PAR2-AP and capsa-
icin had no effect of withdrawal (Fig.
8e). Thus, PAR2 sensitizes responses to
capsaicin by a mechanism that depends
on TRPV1.
To determine whether PKC mediates
this sensitization, we injected GFX locally
into the paw. In C57BL/6 mice treated
with GFX vehicle, coinjection of PAR2-AP
(1 ng/paw) and capsaicin (1 g/paw) de-
creased the latency of paw withdrawal
(Fig. 8e). Pretreatment with GFX (1 g/
paw) completely inhibited the synergic ef-
fect of capsaicin and PAR2-AP on decreas-
ing the withdrawal latency at all times.
After 3 hr, animals pretreated with GFX
showed an increased nociceptive thresh-
old. GFX injected alone did not affect the
latency of paw withdrawal at 0 –2 hr but
slightly decreased withdrawal latency at 3
and 4 hr. Thus, PAR2 activation sensitizes
TRPV1 to induce thermal hyperalgesia by
a mechanism that is dependent on PKC.
PAR2 activation enhanced capsaicin-
stimulated release of SP and CGRP in
the spinal cord
The intraplantar injection of PAR2 ago-
nists causes thermal hyperalgesia in part
by stimulating the release of neuropep-
tides from the central projections of DRG
in the dorsal horn of the spinal cord
(Vergnolle et al., 2001). To determine
whether PAR2 activation sensitizes
TRPV1-stimulated neuropeptide release
from the central projections of DRG neu-
rons, we measured secretion of SP and CGRP from superfused
slices of the rat spinal cord. Superfusion with capsaicin (0.5 or 1
M) stimulated release of SP- and CGRP-LI from the spinal cord
(Fig. 9a,b). Pretreatment with PAR2-AP (10 M, 20 min) en-
hanced capsaicin-stimulated release of SP-LI by 2-fold and
CGRP-LI by1.6-fold compared with vehicle, whereas PAR2-RP
(10 M, 20 min) was ineffective. Thus, activation of PAR2 sensi-
tizes TRPV1-mediated release of neuropeptides from the central
projections of DRG neurons in the dorsal horn of the spinal cord,
where they mediate nociceptive transmission.
Discussion
PAR2 has been recently suggested to play a role in nociceptive
signaling (Hoogerwerf et al., 2001; Kawabata et al., 2001a;
Vergnolle et al., 2001; Coelho et al., 2002). However, the mecha-
nism by which proteases that activate PAR2 induce hyperalgesia is
unknown. From a combination of observations in transfected cell
lines, cultured DRG, spinal cord slices, and intact animals, we
conclude that PAR2 sensitizes TRPV1 through a PKC-dependent
mechanism, and TRPV1 is required for PAR2-induced thermal
hyperalgesia.
Figure 8. Mechanisms of PAR2-induced thermal hyperalgesia in mice. PAR2-AP or PAR2-RP was administered by intraplantar
injection, and latency of paw withdrawal was measured in C57BL/6 mice (a, c, d, f ) or TRPV1/ and TRPV1/mice (b, e). a,
PAR2-AP decreased the latency of withdrawal, which was inhibited by systemic administration of capsazepine (capsaz; 35 mg/kg,
s.c.). b, PAR2-AP also decreased the latency of withdrawal in TRPV1
/mice but not TRPV1/mice. c, The effect of PAR2-AP
on withdrawal latency was dose-related. d, Coinjection of PAR2-AP and capsaicin (Cap) at doses that alone did not cause hyper-
algesia decreased the latency of paw withdrawal. e, The synergistic effects of coinjected PAR2-AP and capsaicin were observed in
TRPV1/ but not TRPV1/mice. f, Intraplantar injection of GFX (1g/paw) inhibited the synergistic effects of PAR2-AP and
capsaicin. veh, Vehicle. *p 0.05 compared with basal withdrawal latency (b, d–f ) or PAR2-AP-induced hyperalgesia (a, c); n	
6 – 8 mice per group.
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PAR2 sensitizes TRPV1 to cause thermal hyperalgesia
Our conclusion that PAR2 sensitizes TRPV1 is based on several
observations. First, in HEK-TRPV1 cells and DRG neurons,
PAR2 agonists increased the magnitude of the Ca
2 response to
capsaicin and the proportion of capsaicin-responsive neurons.
Thus, activation of PAR2 both magnifies TRPV1 responses and
recruits additional neurons that were previously unresponsive to
capsaicin. Second, PAR2 agonists induced a sustained potentia-
tion of TRPV1 currents in DRG neurons. Third, intraplantar
injection of PAR2-AP induced a persistent thermal hyperalgesia
that was mediated by TRPV1 because it was inhibited by antago-
nism or deletion of this channel. The finding that coinjection of
nonhyperalgesic doses of PAR2-AP and capsaicin caused hyper-
algesia that was also entirely dependent on TRPV1 confirms that
PAR2 sensitizes TRPV1 in vivo. Finally, superfusion of spinal cord
slices with PAR2-AP potentiated TRPV1-mediated release of SP
and CGRP. These neuropeptides derive from the central projec-
tions of DRG neurons in the spinal cord, where they mediate
PAR2-induced hyperalgesia (Hoogerwerf et al., 2001; Kawabata
et al., 2001a; Vergnolle et al., 2001; Coelho et al., 2002). In exper-
iments with transfected cells, cultured neurons, spinal cord slices,
and intact animals, we used a synthetic peptide and proteases to
activate PAR2. PAR2-AP (SLIGRL-NH2) selectively activates this
receptor and does not activate other known PARs. PAR2-RP,
which does not activate PAR2, did not sensitize TRPV1-induced
Ca 2 signals or currents and had no effect on capsaicin-induced
neuropeptide release or thermal hyperalgesia, confirming speci-
ficity. We have previously reported that the effects of trypsin and
tryptase on DRG neurons are desensitized by PAR2-AP, and their
hyperalgesic actions are not detected in PAR2-deficient animals,
suggesting that they induce hyperalgesia by activation of this re-
ceptor (Steinhoff et al., 2000; Vergnolle et al., 2001).
PAR1 is also coexpressed with CGRP in DRG neurons, and
PAR1 agonists induce neurogenic inflammation (de Garavilla et
al., 2001). Although PAR1 was coexpressed with TRPV1 in HEK-
TRPV1 cells and DRG neurons, PAR1-AP did not sensitize
TRPV1 Ca 2 responses. This finding is consistent with the report
that PAR1 activation induces thermal and mechanical analgesia
rather than hyperalgesia (Asfaha et al., 2002). The mechanism of
the differential effects of PAR1 and PAR2 agonists on TRPV1
agonists is unknown, although activation of divergent signaling
pathways is a probable explanation. Although both PAR1 and
PAR2 couple to PLC and similarly mobilized intracellular Ca
2
in HEK-TRPV1 and DRG neurons, PAR1 more prominently reg-
ulates adenylyl cyclase, and PAR1 and PAR2 regulate mitogen-
activated protein kinases by different mechanisms (for review,
see Ossovskaya and Bunnett, 2004). Further investigation is re-
quired to define the mechanism of the different effects of PAR1
and PAR2 on TRPV1 in neurons.
PLC and PKC mediate PAR2-induced sensitization of TRPV1
Inflammatory agents (e.g., bradykinin, ATP, PGE2, and NGF)
can indirectly sensitize TRPV1 to cause hyperalgesia. It is impor-
tant to understand the mechanisms of this sensitization because it
may explain the hyperalgesic effects of diverse inflammatory me-
diators. Our observation that an inhibitor of PLC prevented
PAR2-induced sensitization of TRPV1 is expected because PAR2
couples to PLC with subsequent formation of InsP3 and DAG,
followed by mobilization of Ca 2 and activation of PKC. PLC
can regulate TRPV1 by controlling the levels of its substrate, PIP2,
which directly binds and inhibits TRPV1 (Chuang et al., 2001;
Prescott and Julius, 2003). Thus, bradykinin and NGF, which
activate PLC, release TRPV1 from PIP2-mediated inhibition.
PAR2 could similarly sensitize TRPV1 by reducing PIP2 levels.
However, PLC also regulates TRPV1 by DAG formation and
subsequent activation of PKC, which in turn phosphorylates and
sensitizes TRPV1 (Tominaga et al., 2001; Vellani et al., 2001;
Crandall et al., 2002; Prescott and Julius, 2003). Our observation
that two distinct inhibitors of PKC prevented PAR2-induced sen-
sitization of TRPV1 suggests that the activation of PKC plays a
major role in PAR2-induced sensitization of TRPV1.
We do not know which isozyme of PKC is responsible for
PAR2-induced sensitization of TRPV1. There are at least 11 PKC
isozymes, some of which make major contributions to nocicep-
tion. An inhibitor of the,1,2, and  PKC isozymes (Go¨6976)
prevented sensitization in HEK cells and neurons, suggesting an
involvement of at least these isozymes, which have been impli-
Figure 9. PAR2 activation sensitizes TRPV1-mediated release of SP ( a) and CGRP ( b). Slices
of dorsal horn of the spinal cord were pretreated with vehicle (Veh.) or PAR2-AP or -RP (10M)
for 20 min and then challenged with capsaicin (0.5 or 1 M). Pretreatment with PAR2-AP
enhances capsaicin-stimulated release of SP-LI and CGRP-LI. *p 0.05 compared with vehicle
or PAR2-RP; n	 6 – 8 rats.
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cated in nociception. PKC, which is coexpressed with SP and
CGRP in DRG neurons (Cesare et al., 1999; Olah et al., 2002),
mediates upregulation of CGRP expression during chronic treat-
ment with opioids (Belanger et al., 2002) and may enhance in-
flammatory pain (Olah et al., 2002). PKCparticipates in inflam-
matory thermal hyperalgesia (Igwe and Chronwall, 2001) and in
persistent pain (Miletic et al., 2000). PKC contributes to persis-
tent neuropathic pain but not acute pain (Malmberg et al., 1997).
Although Go¨6976 does not inhibit PKC, this isoform plays a
major role in pain transmission (Khasar et al., 1999) and the
regulation of TRPV1 (Cesare et al., 1999). Thus, we cannot ex-
clude the contribution of PKC to PAR2-induced sensitization of
TRPV1. Moreover, because PAR2-dependent sensitization of
TRPV1 is remarkably sustained, different isoforms of PKC may
contribute to sensitization at different times, as reported for the
contribution of PKC to mechanical hyperalgesia (Aley et al.,
2000).
Additional mechanisms may also regulate TRPV1. For exam-
ple, PGE2 sensitizes TRPV1 responses by a protein kinase
A-mediated mechanism (Hu et al., 2002; Rathee et al., 2002; Mo-
hapatra and Nau, 2003), whereas bradykinin transactivates
TRPV1 through the generation of 12-lipoxygenase metabolites of
arachidonic acid (Shin et al., 2002). PAR2 stimulation induces
release of arachidonic acid and PGE2 from epithelial cells (Kong
et al., 1997), and these mechanisms could also contribute to
PAR2-induced sensitization of TRPV1. However, inhibitors of
cyclooxygenase (indomethacin and ibuprofen) and lipoxygenase
(5,8,11,14-eicosatetraynoic acid) do not affect PAR2-mediated
sensitization of TRPV1 Ca 2 signaling in HEK cells (N. W. Bun-
nett, unpublished observation).
PAR2 activation induces phosphorylation of TRPV1
TRPV1 is regulated in part by its phosphorylation state. Dephos-
phorylation of TRPV1 by calcineurin, a Ca 2- and calmodulin-
dependent kinase, can desensitize capsaicin responsiveness (Do-
cherty et al., 1996), whereas phosphorylation may sensitize
TRPV1 (Numazaki et al., 2002). TRPV1 contains 16 Ser and Thr
residues that are potential sites for PKC-dependent phosphory-
lation. Phorbol esters and ATP, which potentiate the TRPV1 cur-
rent and reduce the temperature threshold for activation, induce
phosphorylation of TRPV1 (Numazaki et al., 2002). This process
appears to increase the probability that TRPV1 will open in re-
sponse to agonists (Vellani et al., 2001). Our results show that
PAR2 activation induces phosphorylation of TRPV1. Thus, it is
likely that PAR2 agonists similarly induce phosphorylation of
TRPV1 by a PKC-dependent mechanism to regulate channel
gating.
PAR2 regulates the excitability of nociceptive neurons
We found that PAR2 activation by brief exposure to PAR2-AP,
trypsin, or tryptase caused a sustained decrease in the rheobase of
nociceptive neurons, indicative of an increase in their electrical
excitability. In support of our results, PAR2 activation of S-type
neurons in the submucosal plexus also causes a sustained de-
crease in rheobase and an increase in input resistance (Reed et al.,
2003). The mechanism of the increased excitability of DRG neu-
rons remains to be determined, although alterations in activity of
ion channels other than TRPV1 may contribute. DRG neurons
express multiple voltage-gated channels for Na, Ca 2, and K
ions that are regulated directly by G-proteins or by second mes-
senger kinases. For example, PKC regulates a tetrodotoxin-
resistant Na channel in nociceptive neurons (Gold et al., 1998)
and PAR2 may regulate the activity of this channel and thereby
enhance sensitivity. Alterations in membrane potential can also
affect TRPV1 activity. The TRPV1 current in DRG neurons in-
creases on membrane depolarization, suggesting that voltage
serves as an intrinsic coactivator of this channel (Ahern and
Premkumar, 2002). Thus, PAR2 activation increases the excit-
ability of neurons by varying mechanisms and may sensitize their
responses to agonists of TRPV1 or other agents to result in exac-
erbated inflammation and hyperalgesia.
In summary, we have identified a novel mechanism by which
proteases cleave PAR2 on sensory nerves and sensitize TRPV1 to
induce sustained thermal hyperalgesia. Sensitization requires ac-
tivation of PLC and PKC and is probably mediated by direct
phosphorylation of TRPV1 to enhance channel gating. PAR2-
induced sensitization of TRPV1 causes enhanced release of neu-
ropeptides in the spinal cord and exacerbated thermal pain. Pro-
teases that activate PAR2, such as mast cell tryptase, coagulation
factors VIIa and Xa, and extrapancreatic trypsins, are released
and generated during injury and inflammation, which suggests
that this mechanism plays an important role in these states. Al-
though antagonists of PAR2 are not currently available, our re-
sults suggest that inhibitors or antagonists of proteases, TRPV1,
and PKC may offer new therapies for treatment of sustained in-
flammatory pain.
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